Tumors often evade immune surveillance, making it critical to understand how effector immune cells contribute to anti-tumor immunity. Immune cell-mediated cancer cell killing assays provide a powerful tool to evaluate therapeutic candidates by measuring their ability to enhance or suppress immune effector function.

At Axela Biosciences, we offer a comprehensive portfolio of assays to assess the tumor-killing capacity of primary and engineered T cells, natural killer (NK) cells, and macrophages. Our platforms deliver sensitive, accurate, and direct measurements of immune cell killing potency to support immunotherapy development.